dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· April 15, 2026

Wells Fargo Gets Three Price Target Cuts in One Day: Is the ROTCE Recovery Story Falling Apart?

View original at finance.yahoo.com
Wells Fargo Gets Three Price Target Cuts in One Day: Is the ROTCE Recovery Story Falling Apart? Quick Read Wells Fargo (WFC) got hit with price target cuts from Barclays, Bank of America, and Piper Sandler following Q1 earnings, with BofA making the sharpest reduction to $95 from $107…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Wells Fargo earnings excluding tax benefit were light, with net interest income, fees, and expenses all coming in below expectations

    60% confidence
  • Wells Fargo's net interest margin contraction of 13 basis points quarter-over-quarter is the real sticker shock

    60% confidence
  • The path to 17% to 18% ROTCE is narrowing for Wells Fargo

    60% confidence
  • Net interest margin contraction raises further doubts around the ROTCE improvement thesis

    60% confidence
  • Wells Fargo asset quality remained stable and buybacks continued

    60% confidence

Data points we hold from this source

Wells Fargo & Company · eps estimate fy20266.72 USD
Wells Fargo & Company · eps estimate fy20277.36 USD
Wells Fargo & Company · price target108 USD
Wells Fargo & Company · ytd stock performance-13 percent
Wells Fargo & Company · net interest margin change-13 basis_points
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,995
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,995 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Wells Fargo Gets Three Price Target Cuts in One Day: Is the ROTCE Recovery Story Falling Apart?: Source | Via News | fr.via.news